CD8A and neoplasm: Although fully hypothetical at this stage of the clinical development of TG4010, it could be that functional MUC1-specific CD8+ T cells primed by TG4010, infiltrate the tumor, kill MUC1-expressing cancer cells, and thus release additional TAA that are subsequently presented to the immune system to generate more functional TAA- and neo-epitope-specific CD8+ T cells.